Novartis And China’s MOH Collaborate On Healthcare Safety And Hospital Management Program
This article was originally published in PharmAsia News
Executive Summary
Novartis China and partners Harvard Medical International, the International Health Exchange and Cooperation Center under China's Ministry of Health recently kicked off an academic exchange and collaboration program. The three-year program includes two major conference themes - healthcare safety and hospital top management forum and a Chinese hypertension expert summit. PHMI and Novartis will, according to the field's local and international issues, plan meeting topics and invite authorities in charge of healthcare policies from China and overseas healthcare institutions. The platform seeks to introduce local medical developments as well as share the latest global management experience and best practices in healthcare treatment. (Click here for more - Chinese language)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.